Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.

NCT02000453 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02000453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02000453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
December 20, 2013
Completion date
August 8, 2014
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative